Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 6, pp 1257–1263

Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer

  • Yen-Shen Lu
  • Dar-Ren Chen
  • Ling-Min Tseng
  • Dah-Cherng Yeh
  • Shou-Tung Chen
  • Chia-Ming Hsieh
  • Hwei-Chung Wang
  • Hsien-Tang Yeh
  • Sung-Hsin Kuo
  • Chiun-Sheng Huang
Original Article

DOI: 10.1007/s00280-010-1401-2

Cite this article as:
Lu, YS., Chen, DR., Tseng, LM. et al. Cancer Chemother Pharmacol (2011) 67: 1257. doi:10.1007/s00280-010-1401-2
  • 169 Downloads

Abstract

Purpose

Docetaxel, capecitabine, and cisplatin are effective chemotherapeutic agents for breast cancer with significant synergistic cytotoxicity demonstrated by in vitro studies. The purpose of this study was to assess the efficacy of a combination of docetaxel, capecitabine, and cisplatin (TXP) in patients diagnosed with locally advanced breast cancer (LABC).

Methods

Patients (n = 42) with chemotherapy-naïve LABC (stage IIIa or IIIb) were enrolled. The chemotherapeutic regimen consisted of 4–6 cycles of intravenous docetaxel (60 mg/m2) and cisplatin (50 mg/m2) on day 1, plus oral capecitabine (1,800 mg/m2/day) on day 1–14, repeated every 3 weeks. Upon completion of therapy, the primary tumor was resected when not contraindicated.

Results

Median patient age was 48.5 years (range 31–66 years). Median tumor size was 6.8 cm (range 2.7–15 cm), 29 patients were node-positive, and 12 patients were hormone receptor positive. A total of 216 cycles (median 5; range 3–6 cycles) were administered without prophylactic G-CSF. The predominant toxicities were grade 3/4 neutropenia (30%/28%) and no grade 3/4 thrombocytopenia, febrile neutropenia, or grade 4 non-hematological toxicities were observed. Grade 3 non-hematological toxicities included hand-foot syndrome (5.6%) and vomiting (0.5%). The overall clinical response rate was 97.6% (41/42). Six of the 42 patients (14.3%) achieved a complete pathological response. Of 22 patients who completed 6 cycles of combination treatment, the complete pathological response was 27.3% (6/22).

Conclusions

A combination of TXP can be administered safely without prophylactic G-CSF, and appears to be an effective neoadjuvant regimen in patients with LABC.

Keywords

Locally advanced breast cancer Neoadjuvant chemotherapy Docetaxel Cisplatin Capecitabine 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Yen-Shen Lu
    • 1
  • Dar-Ren Chen
    • 2
  • Ling-Min Tseng
    • 3
  • Dah-Cherng Yeh
    • 4
  • Shou-Tung Chen
    • 2
  • Chia-Ming Hsieh
    • 5
  • Hwei-Chung Wang
    • 6
  • Hsien-Tang Yeh
    • 7
  • Sung-Hsin Kuo
    • 1
  • Chiun-Sheng Huang
    • 8
  1. 1.Department of OncologyNational Taiwan University HospitalTaipeiTaiwan, ROC
  2. 2.Department of SurgeryChanghua Christian HospitalChanghuaTaiwan, ROC
  3. 3.Department of SurgeryTaipei Veterans General Hospital and National Yang-Ming UniversityTaipeiTaiwan, ROC
  4. 4.Department of SurgeryTaichung Veterans General HospitalTaichungTaiwan, ROC
  5. 5.Department of SurgeryTaiwan Adventist HospitalTaipeiTaiwan, ROC
  6. 6.Department of SurgeryChina Medical University HospitalTaichungTaiwan, ROC
  7. 7.Department of SurgeryLotung Poh-Ai HospitalYilan CountyTaiwan, ROC
  8. 8.Department of SurgeryNational Taiwan University HospitalTaipeiTaiwan, ROC

Personalised recommendations